Molina Healthcare’s third quarter results reflected continued pressure from a challenging medical cost environment, with year-on-year declines in revenue and membership. Management pointed to operational execution on recent contracts and modest margin stability as key drivers, despite persistent utilization pressure in Medicaid and Medicare. CEO Joe Zubretsky described the quarter’s Medicaid pre-tax margin as a “trough” in a multi-year cycle, emphasizing that recent rate updates helped offset higher medical costs. Zubretsky added, “The imbalance between rates and trend appears to have stabilized, which supports our view that current Medicaid margins represent the trough in a multi-year cycle.”

Is now the time to buy MOH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Molina Healthcare’s Q3 earnings call

• Andrew Mok (Barclays) asked about the drivers behind Medicaid margin improvement and sequential EPS strength. CEO Joe Zubretsky attributed the improvement to recent rate updates and normal seasonality, while CFO Mark Keim clarified that without the Florida CMS drag, margins would look even better.

• Kevin Fischbeck (Bank of America) questioned the impact of work requirements on Medicaid member acuity. Zubretsky explained that most states are interpreting federal guidance in ways that promote continued enrollment, with Nebraska serving as an early example of a more moderate impact than expected.

• John Stansel (J.P. Morgan) sought insight on the early performance and break-even path of the Florida CMS contract. Zubretsky described the implementation as “nearly flawless” and expects operational improvements to drive a transition from initial losses to break-even by year two.

• A.J. Rice (UBS) pressed on the breadth of margin recovery opportunities across Molina’s Medicaid portfolio. Zubretsky noted that while most states remain slightly underfunded, broad-based rate cycle improvements are expected to gradually restore actuarial soundness.

• Sarah James (Cantor Fitzgerald) inquired about the pacing of Medicaid membership losses from work requirements. Keim clarified that approximately 6% attrition is expected in 2027, with additional reductions stretching into 2028 and 2029 as states phase in new policies.

Catalysts in upcoming quarters

In the coming quarters, our analysts will focus on (1) the pace at which Medicaid margins recover as new rate cycles take effect, (2) the operational and financial ramp-up of the Florida CMS contract, and (3) the timing and outcome of legal proceedings affecting large contract implementations in Georgia and Texas. Trends in medical cost utilization and state-level policy changes regarding eligibility will also be key signals to monitor.

Molina Healthcare currently trades at $213.60, in line with $214.79 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

The best stocks for high-quality investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.